Company profile: Pacira BioSciences
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical products and pain management technologies, including EXPAREL, a local anesthetic used during surgery to manage pain and reduce opioid use; ZILRETTA, an extended-release injectable for osteoarthritis knee pain; ioveraº, a cryoanalgesia system delivering immediate relief; and pMVL, a multivesicular liposome drug delivery technology.
Products and services
- EXPAREL: A clinical-grade local anesthetic used intraoperatively to numb the surgical area for several days, managing postoperative pain and curbing opioid use through prolonged local numbing
- Ioveraº: A medical-grade cryoanalgesia system that applies targeted cold therapy to peripheral nerves, delivering immediate pain relief that can persist for up to three months
- ZILRETTA: An extended-release injectable suspension engineered for osteoarthritis knee pain, producing significant relief for up to 12 weeks through a sustained-release formulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pacira BioSciences
Synergia Medical
HQ: Belgium
Website
- Description: Provider of optoelectronic neurostimulation devices and platforms, including NAO.VNS for drug-resistant epilepsy via Vagus Nerve Stimulation, and technologies such as non-metallic encapsulation, fast wireless charging, custom optical leads, and miniaturized photovoltaic cells to advance therapies for chronic pain, Parkinson’s disease, epilepsy, sleep apnea, and depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synergia Medical company profile →
Rinat Neuroscience
HQ: United States
Website
- Description: Provider of therapeutic antibody assets in neuroscience, formed in 2001 via a broad license from Genentech’s spinout of its key neuroscience assets, leveraging 15 years of Genentech R&D investment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rinat Neuroscience company profile →
Labrys Biologics
HQ: United States
Website
- Description: Provider of treatments for chronic migraine, developing RN-307, an antibody for chronic migraine, with worldwide rights acquired from Pfizer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Labrys Biologics company profile →
Kernel
HQ: United States
Website
- Description: Provider of non-invasive brain-recording technologies, including Kernel Flow2, a time-domain fNIRS and EEG neuro measurement platform, and Kernel Flow, a multimodal headset combining hemodynamic and EEG data. Services include study design consulting, data management software, custom fNIRS/TD-fNIRS analysis development, and automated quality control metrics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kernel company profile →
Neos Therapeutics
HQ: United States
Website
- Description: Provider of oral drug delivery solutions developing controlled time-release technologies, offering CNS stimulants for ADHD (ADZENYS XR-ODT; COTEMPLA XR-ODT), Karbinal ER for allergic conditions, prescription fluoride supplements (Poly-Vi-Flor, Tri-Vi-Flor), the RxConnect patient access program, and AR101 (enzastaurin), a therapeutic candidate for vascular Ehlers-Danlos Syndrome (VEDS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pacira BioSciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pacira BioSciences
2.2 - Growth funds investing in similar companies to Pacira BioSciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pacira BioSciences
4.2 - Public trading comparable groups for Pacira BioSciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →